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Abstract
Little is known about the behavior of the ovarian sur-
face epithelium (OSE), which plays a central role
in ovarian cancer etiology. It has been suggested
that incessant ovulation causes OSE changes leading
to transformation and that high gonadotropin levels
during postmenopause activate OSE receptors, in-
ducing proliferation. We examined the chronology
of OSE changes, including tumor appearance, in a
mouse model where ovulation never occurs due to
deletion of follitropin receptor. Changes in epithelial
cells were marked by pan-cytokeratin (CK) staining.
Histologic changes and CK staining in the OSE in-
creased from postnatal day 2. CK staining was ob-
served inside the ovary by 24 days and increased
thereafter in tumor-bearing animals. Ovaries from a
third of aged (1 year) mutant mice showed CK deep
inside, indicating cell migration. These tumors re-
sembled serous papillary adenoma of human ovaries.
Weak expression of GATA-4 and elevation of PCNA,
cyclooxygenase-1, cyclooxygenase-2, and platelet-
derived growth factor receptors A and B in mutants
indicated differences in cell proliferation, differen-
tiation, and inflammation. Thus, we report that OSE
changes occur long before epithelial tumors appear
in FORKO mice. Our results suggest that neither in-
cessant ovulation nor follicle-stimulating hormone re-
ceptor presence in the OSE is required for inducing
ovarian tumors; thus, other mechanisms must con-
tribute to ovarian tumorigenesis.
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Introduction
The cell type of ovarian cancer is age-dependent. Aggres-
sive hormone-secreting granulosa cell tumors are more
frequent in young women [1], but epithelial ovarian neopla-
sia predominates in older and menopausal women [2]. The
ovarian surface epithelium (OSE) is a modified pelvic
mesothelium that covers the ovary [3]. OSE cells make up
a single layer, varying in type from simple squamous to
cuboidal to low pseudostratified columnar epithelial cells, which
participate actively in the mechanism of gonadotropin-induced
ovulatory follicular rupture [4,5]. Although the majority of ovar-
ian cancers [epithelial ovarian cancer (EOC)] in aging women
are thought to arise from the OSE [4,6,7], there are some
arguments as to their origin [7,8]. EOC is classified into four
main subtypes: serous, mucinous, endometrioid, and clear cell,
based mainly on histologic differences. EOC is the fourth most
common cause of cancer death among women and has the
highest mortality rate among gynecologic cancers [9]. Despite
improved knowledge of etiology, aggressive cytoreductive sur-
gery, and modern combination chemotherapy, the 5-year sur-
vival rate is < 40% [9]. Lack of adequate diagnostic screening
test for early disease detection and rapid progression to
chemoresistance have been major stumbling blocks in se-
curing appreciable improvements. Experimental models for
human diseases are critical, not only to understand the bio-
logic and genetic factors that influence the disease process
but also to develop strategies for treatment. In particular, experi-
mental models of ovarian tumor development, which mimic
perimenopausal and postmenopausal states in women, could
enhance efforts to understand molecular changes that occur
during development and progression to ovarian carcinoma.
Recent literature reveals that the proliferation and migration
of the OSE are regulated by hormones, growth factors, and
cytokines. Gonadotropins, including follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH), have been impli-
cated in OSE proliferation, migration, and protection from
apoptosis in humans, mice, rats, and cows in vivo and in vitro
[10–14]. Steroid hormones such as estrogen, progesterone,
and androgen also modulate the OSE [3,4]. Besides these,
other regulators of the OSE include epidermal growth factor
(EGF) [15] and platelet-derived growth factor (PDGF) [16].
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Wehave previously reported that in our follitropin receptor
knockout (FORKO) mouse model, pituitary gonadotropins
(FSH and LH) and ovarian androgen levels are significantly
increased, whereas estrogen levels remain very low [17]—
an endocrine profile that is similar, in many respects, to
postmenopausal conditions and other hormone-related dis-
orders in women; furthermore, by 12 months, > 90% of
FORKO mice developed various kinds of ovarian pathology,
including neoplasms of sex cord–stromal type, as well as
cysts [17]. In addition, our recent findings indicate that
FORKO mice have a thicker OSE at an early age [18] and
increase the expression of tight junction proteins exclusively
in these cells [19]. The presence of platelet-derived growth
factor receptors (PDGFRs) and hormonal regulation in the
OSE, as well as different expression patterns between wild-
type (WT) and FORKO [20] mice, prompted us to examine
the postnatal chronology of the OSE in mutants. We hypoth-
esized that the OSE of FORKO ovaries undergoes early and
progressive changes culminating in tumors. In testing this
hypothesis, our objectives were: 1) to determine how the
OSE changes during development in an aberrant hormonal
environment; and 2) to determine the presence of ovarian
epithelial tumor in aged FORKO mice. Herein we report that
ovarian epithelial tumors also occur in FORKO mice that are
sterile and never ovulate. Thus, our results challenge the
absolute requirement of incessant ovulation for precipitating
EOC and suggest that other conditions also significantly
contribute to the disease process.
Materials and Methods
Animals
The studies described in this report were performed
according to accepted and approved guidelines of the insti-
tutional animal care and ethics committee. FORKO mice
were established as previously described [17]. Animals were
housed under controlled temperature and constant light
(12 hours of light, 12 hours of darkness), with food and
water provided ad libitum. The female mice used in this
experiment were derived by breeding F2 generation hetero-
zygotes of sv129 background. They were genotyped by
polymerase chain reaction according to methods we have
described recently [21]. Age-matched mutants and WT mice
were compared in each experiment.
Histologic Analysis
Animals were sacrificed by CO2 inhalation, and all internal
organs were examined for visual signs of abnormalities. The
ovaries were cleaned of extraneous tissues and then fixed
in 10% formalin at room temperature for 16 to 20 hours. All
tissues were embedded in paraffin, sectioned, and stained with
hematoxylin and eosin (H&E), according to standard histologic
procedures that we have used in previous studies [21]. The
classification of ovarian pathology, including tumor type, was
performed according to the descriptions provided in the atlas
on basic histopathology [22] and pathology of the female
genital tract, with special reference to the mouse [23,24].
Confocal Microscopy Immunofluorescence Study
of Cytokeratin
Immunofluorescence was performed on paraffin-embedded
sections. Briefly, formaldehyde-fixed ovaries were embedded
in paraffin and sectioned at 5 mm. Following deparaffinization,
tissue sections weremicrowaved in citric acid solution (0.01 M
citric acid solution containing 0.01 M sodium citrate, pH 6.0)
to unmask antigenic sites. Sections were treated with 3%
hydrogen peroxide for 5 minutes to block endogenous perox-
idase. After blocking in 5% nonimmune serum for 1 hour at
room temperature, sections were incubated overnight at 4jC
with pan-cytokeratin (CK) antibody (1:150; Sigma, St. Louis,
MO). Fluorescein-conjugated goat anti-mouse secondary
antibody was used at a dilution of 1:200. Images were cap-
tured following confocal microscopy.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
sections using the Dako Cytomation Liquid DAB Substrate
Chromogen Staining System (Dako, Carpinteria, CA). Antigen
retrieval procedure was performed for localization of PCNA,
PDGFR-a, PDGFR-b, inhibin-a, GATA-4, cyclooxygenase-1
(COX-1), and cyclooxygenase-2 (COX-2). Sections were
treated with 3% hydrogen peroxide for 5 minutes to block en-
dogenous peroxidase. Rabbit antiserum to the N-terminal pep-
tide of inhibin-a subunit (from Dr. B. D. Schanbacher, formerly
of the USDA, Clay Center, NE) was used at a dilution of 1:1000.
As this reacts with the free a-subunit and inhibin dimer, we as-
sume that all forms of inhibin are revealed. 3b-Hydroxysteroid
dehydrogenase (3b-HSD) antibody was provided by Dr. A. H.
Payne (Stanford University, Palo Alto, CA). This rabbit anti-
serum produced against the recombinant mouse 3b-HSD1 pro-
tein was used at a dilution of 1:1000. Antibodies to COX-1
(1:500) and COX-2 (1:750) were a gift of Dr. S Kargman (Merck
Frosst, Kirkland, QC). For PCNA, after antigen retrieval and
quenching of endogenous peroxidase, sections were treated
with 0.3% Triton X-100 for 10 minutes and incubated overnight
at 4jC with monoclonal anti-mouse PCNA (1:300). Goat anti-
bodies to the transcription factor GATA-4 were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and used at
1:400 dilution. PDGFR-a and PDGFR-b antibodies (kindly pro-
vided by Dr. Carl-Henrik Heldin, Ludwig Institute for Cancer
Research, Uppsala, Sweden) were diluted in a blocking serum
solution at 1:400 and 1:300, respectively. In negative controls,
normal serum was substituted for primary antibody in the first
reaction. The corresponding rabbit secondary antibody (1:200)
was used for subsequent processing. Signals were amplified
with avidin-biotinylated horseradish peroxidase developed with
diaminobenzidine, counterstained with hematoxylin, and dehy-
drated again. Sections were analyzed under a light microscope.
Results
Chronology of the Alteration of OSE Cells as Early
as 2 Days after Birth
As most FORKO mice acquire ovarian tumors by 12 to
15 months [17], we performed immunofluorescence analysis
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using the cytokeratin antibody of ovaries as early as 2 days
to 8 months to determine the progressive alteration of the
OSE in FORKO mice. As cytokeratin expression is an ac-
ceptable marker for the identification of epithelial cells, we
used a pan-cytokeratin antibody to reveal the OSE [25]. The
OSE in FORKO ovaries is thicker than that in WT mice. In 2-
and 10-day ovaries, CK expression was evident only in the
OSE of both WT and FORKO, but the expression of CK in
FORKO ovaries was higher (Figure 1). As early as 24 days,
epithelial cells were found to migrate inside some FORKO
ovaries. In contrast, none of the WT 24-day ovaries was
stained by CK inside the ovary. By 8 months of age, more
epithelial cells had migrated inside the FORKO ovaries and
cysts had also been found (data not shown). These results
confirm that: 1) abrogating follicle-stimulating hormone re-
ceptor (FSH-R) signaling affects ovarian development as
Figure 1. Epithelial cell immunofluorescence staining (arrows) with CK antibody in ovaries at different ages. Green (fluorescein isothiocyanate) indicates a positive
signal, and red shows DAPI staining in the nucleus. (a) Immunofluorescence staining of the 2-day-old ovaries of WT and FORKO mice. Note that CK immuno-
fluorescence staining is just located in the OSE and that positive signal is much higher in FORKO OSE than in WT. Original magnification, 40. (b) Immunostaining
of CK in the 10-day-old ovaries of WT and FORKO mice. Note that there is also no positive staining in WT ovary except the OSE and that positive staining in
FORKO ovary is higher than that in WT ovary (arrow). Star represents ovarian bursa. Original magnification, 40. (c) Immunofluorescence staining of the 24-day-
old ovaries of WT and FORKO mice. Note that CK immunofluorescence staining is located in WT OSE and that positive signal is higher in FORKO OSE;
furthermore, there is a positive signal (green) appearing within the FORKO ovary. Inserts (E V and F V; original magnification, 40) are an enlargement of the white
boxed area in each (original magnification, 10). (d) Immunofluorescence staining result of the 8-month-old ovaries of WT and FORKO mice. Note that there is no
positive staining in WT ovary except the OSE, whereas positive staining appears in some parts within the FORKO ovary. Inserts (G V and H V; original magnification,
40) are an enlargement of the white boxed area in each (original magnification, 10).
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early as 2 days, including effects on the OSE [18]; and 2)
hormonal imbalances in young FORKO mice might induce
the migration and proliferation of the OSE at an early stage.
CK Expression Inside the FORKO Ovary and Aging Effects
To investigate whether alteration of the OSE and migra-
tion of the OSE inside the ovary could be connected to the
induction of late EOC tumors, we also assessed CK expres-
sion and histopathology in FORKO and WT ovaries at 12 to
15 months of age (n = 84 for FORKO; n = 23 for WT). In this
study, we did not check the differences of tumor incidence
between the right and left ovaries of FORKO and WT mice,
as we pooled ovaries from respective groups to get a general
idea of OSE pathology. Typical examples are shown in
Figure 2, and the extent of OSE penetration we found in
the ovarian interior is summarized in Table 1. Pathological
changes attributable to the OSE (Figure 2a) were consistent
with immunofluorescence staining for cytokeratin. In such a
comparison, nearly 30% of aged FORKO ovaries showed
staining deep inside (Figure 2b). On the contrary, < 10% of
WT age-matched ovaries were found to have cysts, which
were lined with only one layer of epithelial cells.
FORKO Ovarian Tumor Pathology
Majority of the CK-positive FORKO ovaries were identi-
fied as having ovarian serous papillary cystadenoma or
cystadenocarcinoma, an observation that is also consistent
with the findings of another group studying similar mutants
[26]. Figure 2a shows typical examples of ovarian serous
papillary cystadenocarcinoma by H&E. They are composed
of fronds and branching papillary projections of cuboidal to
columnar cilia epithelia with occasional vacuoles and eosin-
ophilic cytoplasm resembling human ovarian serous papil-
lary cystadenocarcinoma. Figure 3 further reveals that there
are two more kinds of tumors in these groups of FORKO
mutants: serous papillary cystadenoma and granulosa cell
tumor (arrowhead), except ovarian Sertoli-Leydig cell tumor,
as previously reported [17].
Characterization of Tumor Properties
To further confirm the types of ovarian tumors, additional
cell markers for epithelial cell, granulosa cell, and theca cell
tumors were selected and used in serial sections. First,
we selected a CK antibody that recognizes cytokeratins 1,
5, 6, and 8. It is a broad-spectrum antibody that reacts
specifically with a variety of normal, reactive, and neoplastic
epithelial tissues. The antibody reacts with simple cornifying
and noncornifying squamous epithelia and pseudostratified
epithelia and is not reactive in granulosa cell tumors [27].
Thus, we could distinguish OSE-derived tumors from granu-
losa cell tumors that also occur in our mutants. Cytokeratin
staining was confined to normal OSE inWTmice (Figure 2b),
as previously reported by others [25] and in all ages. In
mutant ovaries attributed an OSE-type pathology, strong CK
staining was detected in tumor cells inside the FORKO ovary
(Figure 2b).
Interestingly, absent or weak inhibin-a (Figure 2c) staining
was detectable in neoplastic cells that were stained by CK in
mutant ovaries, in contrast to the staining of granulosa cells in
the remaining follicles of the same ovaries. Inhibin-a subunit
is expressed mainly in granulosa cells, but is also detected
in normal WT OSE and weakly in corpus luteum (CL) (Fig-
ure 2c). Expression of the enzyme 3b-HSD is characteristic
of steroidogenic cells that produce androgen in ovaries. In WT
ovary, 3b-HSD (Figure 2d ) was confined to stromal and theca
cells, CL, and the OSE. In FORKO tumors, 3b-HSD staining
was not detected in cells stained by CK (Figure 2d ), whereas
there were some cells that strongly stained inside papillary
structures. The nature of 3b-HSD expression in these tumors
is different from that in Sertoli-Leydig tumors, as reported
previously [17]. Expression of the marker of epithelial cell
differentiation and the absence of typical markers of granu-
losa cell (a-inhibin) and Sertoli-Leydig tumors (3b-HSD)
strongly indicate their surface epithelial origin [28], as op-
posed to a granulosa or a sex cord–stromal cell origin.
Immunohistochemical Analysis of PCNA in Tumor
Cell proliferation in tissue sections was evaluated by
PCNA. Nuclear staining for PCNA was detected in three
kinds of ovaries, including WT, FORKO, and FORKO tumor
ovaries. Figure 4a shows representative images of PCNA
staining. Visually, the number of cells positive for PCNA in
the epithelial cells of FORKO tumor (Figure 4a) was high. A
small number of OSE cells positive for PCNA were seen in
agedWTand nontumor FORKO ovaries. These data indicate
that epithelial cells in FORKO tumor continue to undergo
active proliferation, whereas the OSE of aged WT and non-
tumor FORKO ovaries remains almost quiescent (Table 2).
Immunohistochemical Analysis of GATA-4 in Tumor
As expression of the transcription factor GATA-4 is re-
portedly lost in most human ovarian serous carcinomas [29],
immunohistochemical analysis of FORKO tumor was of
interest. Our previous work showed that GATA-4 expression
in granulosa cells was decreased in FORKO ovary com-
pared with age-matched WT ovary in immature mice [18].
Here, we demonstrate that GATA-4 is strongly expressed in
the nucleus of epithelial cells of morphologically normal OSE
of WT ovary (Figure 4b). All OSE are intensely positive for
GATA-4 staining in the nucleus. Some cells scattered in the
ovarian stroma are also GATA-4–positive. In FORKO ovary,
GATA-4 staining in the nucleus of the OSE, granulosa cells,
and some stromal cells was weaker than that in WT. In
contrast to the staining of the OSE in WT and FORKO
ovaries, GATA-4 protein expression is lost in FORKO serous
ovarian tumors (Table 2). This indicates that loss of GATA
factors or their cognate regulatory pathways leads to de-
differentiation of epithelial cells, which perhaps contributes
to tumorigenicity.
COX-1 and COX-2 Expression in OSE Tumor
COX-1 and COX-2 are two distinct isoforms that catalyze
the conversion of arachidonic acid to prostaglandins. COX-1
expression is constitutive, whereas COX-2 is expressed in
inflammatory cells and is highly induced by various stimuli
(growth factors, UV, and so on) in a wide variety of cells.
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Figure 2. Ovarian histopathology and immunostaining characteristics of the appearance of ovarian serous papillary cystadenoma in 12- to 15-month-old FORKO
females. Note that epithelial-lined structures in FORKO ovaries mimic human serous ovarian adenocarcinomas. OB = ovarian bursa; EC = epithelial cell. (a) H&E
ovarian histopathology of the appearance of FORKO (A–F) and WT mice (G–H) in 12- to 15-month-old females. (A–F) Ovaries from FORKO females with ovarian
serous papillary cystadenoma. (B, D, and F) Higher magnifications of (A), (C), and (E), respectively. (A) Representative ovary from null mutant showing serous
tumor. Note that the remnant of the ovary is small, with few identifiable follicular structures compared with the large tumor. (C) The common feature of serous
tumors is the presence of a tall, columnar, ciliated epithelial cell lining and clear serous fluid filling the cystic space. (E) Another kind of serous tumor full of clear fluid
and no identifiable follicle structure. (G and H; higher magnification of G) WT ovary from a 13-month-old female mouse containing antral follicles and corpora lutea.
(b) Immunofluorescence staining (arrows) of CK in serial sections from 12-month-old FORKO serous tumor (A–F) and WT ovary (G–H). Note the strong CK
staining in FORKO serous tumors, in contrast to absent specific positive signal in WT ovary, except in OSE cells. Bottom panels (B, D, and F) are the overlay of the
(green) color of immunofluorescence signal and the (red) color of PI for the nucleus. The insets in each are the enlargement of the white boxed area. Arrowhead
shows unspecific staining. Original magnification, 10. (c) Immunostaining (arrows) of inhibin-a in serial sections from 12 (plus)-month-old FORKO serous tumors
(A–F) and WT ovary (G–H). Note that there is absent staining or very weak staining of inhibin-a in cells expressing CK, indicating their epithelial nature. Bottom
panels (B, D, and F) are the enlargement of the black boxed area (A, C, and E). (d) Immunostaining (arrows) of 3-HSD in sections from 12 (plus)-month-old
FORKO serous tumors (A–F) and WT ovary (G–H). Note absent staining or very weak staining of 3-HSD in cells expressing CK. Bottom panels (B, D, and F) are
the enlargement of the black boxed area (A, C, and E).
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Overexpression of COX-1 has been recently reported in
another mouse model of EOC [30]. Figure 4, c and d, shows
representative images of COX-1 and COX-2 staining. High
expressions of both COX-1 and COX-2 were observed in
FORKO ovarian tumor epithelial cells that were inside the
ovary, whereas there was no staining in the OSE of WT and
FORKO ovaries (Table 2). This indicates that cellular over-
expression of COX-1 and COX-2 enzymes might enhance
their tumorigenic potential in FORKO mutants.
Expression of PDGFR-a and PDGFR-
Our previous work revealed that both PDGFR-a and
PDGFR-b are located in the OSE, and their expression is
subject to hormonal regulation [20]. We hypothesized that
the PDGF signal pathway might play an important role in
FORKO ovarian tumorigenesis. In this study, a high expres-
sion of both PDGFR-a (Figure 4e) and PDGFR-b (Figure 4f )
was evident in FORKO ovarian serous tumor (Table 2).
Discussion
FSH-R signaling plays a vital role in ovarian development and
function. To understand the biology of FSH-R–dependent
processes in the ovary, we first produced mice lacking FSH-
R(s) [31]. FORKO mice are sterile despite very high levels
of FSH and LH; by 12 months, the majority of these animals
had developed various kinds of ovarian pathology, including
neoplasms of sex cord–stromal type, as well as cysts [17,
18,31]. Subsequently, in 2-day-old mutant neonates, faster
follicle recruitment was also noted [18]. In continuing our
investigations on these mutants, for the first time, we have
now found alteration in the OSE as early as 2 days after
birth and that ovarian epithelial tumors occurred in the com-
plete absence of ovulation. This finding contrasts with the
theory of incessant ovulation being responsible for in-
ducing EOC in women [32]. Our observations in the FORKO
ovary of thicker OSE from 2 days onward until 24 days
compared with that of age-matched WT, and evidence of
the inward migration of epithelial cells beginning in young
mutants is consistent with other changes occurring within
the ovary [18].
The factors responsible for predisposing the OSE to a tu-
morigenic state are not fully known. Many agents (including
gonadotropins; steroid hormones estrogen, androgen, and
progesterone; and growth factors) could regulate OSE
proliferation and migration. Several reports claim that FSH
Table 1. The Extent of OSE Penetration into the Ovarian Interior as Re-
vealed by Cytokeratins.
WT Ovaries FORKO Ovaries
OSE Inside OSE Inside
2 days + (15)  (15) ++ (9)  (19)
+ (10)
10 days + (16)  (16) ++ (6)  (18)
+ (12)
24 days + (12)  (12) + (12) + 8.3% (12)
8 months + (12)  (12) + (12) + 16.7% (12)
12 months + (23) + 8.7% (23) + (84) + 27.4% (84)
() No signal; (+) strong signal; (++) very strong signal.
The number of ovaries examined is indicated inside the parentheses.
Figure 3. Example of the histopathology and immunostaining characteristics of a serous tumor and an ovarian granulosa cell tumor in one FORKO ovary. (A) H&E
results. (D) Inhibin-a immunostaining. (G) CK immunofluorescence. (B and C; E and F) Enlargement of the boxed area of (A) and (D), respectively. (H) The overlay
of CK-positive color and PI for the nucleus (green = positive signal; red = nucleus). (A) A representative FORKO aged ovary with two clear parts: granulosa cell
tumor (B) and cyst papillary tumor (C). (D) Inhibin-a immunostaining of the FORKO ovary. Note that serous papillary tumor stained very weakly (F), in contrast to
the strong staining of granulosa cell tumor (GCT; E). No CK immunofluorescence positive signal was detected on the part of the GCT, whereas strong CK staining
was found on the part of serous papillary tumor.
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and LH receptors are located in human OSE [11,13,33].
FSH and LH apparently increase the cell proliferation of
normal rabbit, rat, and mouse OSE cells in vivo and in vitro
[10,12,34]. Other studies report FSH and LH stimulation of
cell migration with no effect on proliferation [14]. Receptors
for estrogen, progesterone, and androgen were found at the
mRNA and/or protein level in humans [35] and rats [36] OSE.
Elevated androgen could stimulate the proliferation of ovar-
ian epithelial cells [3]. EGF and PDGF also stimulate OSE
growth significantly [4]. Interestingly, as LH and androgen
levels are elevated early, estrogen level remains consis-
tently low in female FORKO [17], and as some growth fac-
tors such as PDGF and receptors are located in mouse OSE
with alterations in FORKO mutants [20], it is likely that the
hormonal imbalances that occur very early could have con-
tributed to the alterations we have noted. These factors
influenced the expression of regulatory genes in a manner
that induces the proliferation and migration of FORKO OSE
cells. Although this is a plausible scenario, the occurrence
of full-blown OSE tumors in only a certain percentage of
Figure 4. Expression of PCNA (a), GATA (b), COX-1 (c), COX-2 (d), PDGFR-a (e), and PDGFR- (f) in WT (+/+), FORKO (/), and FORKO tumor ovaries. (A, B,
and C) WT, unaffected FORKO, and FORKO tumor ovaries, respectively. (D, E, and F) Higher magnifications of (A), (B), and (C), respectively. (a) Expression of
PCNA in WT (+/+), FORKO (/), and FORKO tumor ovaries. Note that no nucleus of the OSE from WT and unaffected FORKO ovaries was stained by PCNA
antibody, except for immunostaining shown in granulosa cells and some stromal cells, whereas immunostaining was present in the nucleus of some epithelial cells
(arrows) in FORKO tumor ovaries. Arrowheads pointed to nonepithelial cells. (b) Expression of GATA-4 in WT (+/+), FORKO (/), and FORKO tumor ovaries. (A)
Strong GATA-4 staining in WT ovary was confined to the OSE, granulosa cell compartment, and some stromal and thecal cells surrounding the follicles. (B) In
unaffected FORKO ovaries, weak GATA-4 staining was confined to the OSE, granulosa cell compartment, and some stromal and thecal cells surrounding the
follicles. (C) In FORKO ovaries with serous tumor, no GATA-4– immunopositive epithelial cells are seen in the ovary. Note that cells inside the papillary structure
(arrows) indicate immunostaining. For clarity, we have not labeled all positive and negative cells. (c) Expression of COX-1 in WT (+/+), FORKO (/), and FORKO
tumor ovaries. (A) In WT ovaries, COX-1 expression is observed in stromal cells and granulosa cells of some follicles and in CL, with weak immunopositive cells
observed in the OSE. (B) In the unaffected FORKO ovary, weak COX-1– immunopositive cells are observed in some stromal cells and in the OSE. (C) In tumor-
bearing FORKO ovaries, a very strong expression of COX-1 is confined to epithelial cells of a tumor section. (d) Expression of COX-2 in WT (+/+), FORKO (/),
and FORKO tumor ovaries. (A) In WT ovaries, COX-2 expression occurs in stromal cells and granulosa cells of some follicles and in CL cells, with weakly
immunopositive cells in the OSE. (B) In the unaffected FORKO ovary, COX-2 expression is observed in granulosa cells and is strongly observed in the OSE. (C) In
FORKO tumor ovaries, a very strong expression of COX-2 is confined to epithelial cells of a tumor section. Note that COX-2 expression is higher in epithelial cells
and granulosa cells of FORKO ovary than in those of WT ovary. (e and f) Expression of PDGFR-a (e) and PDGFR- (f) in WT (+/+), FORKO (/), and FORKO
tumor ovaries. Strong positive immunoreactivity to PDGFR-a and PDGFR- is detected in CL, and less staining in granulosa cells and OSE cells in WT and
unaffected FORKO ovaries but very intense staining in epithelial cells of FORKO ovarian tumor section.
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mutants and not in all mice experiencing hormonal imbal-
ances is rather intriguing. Such a pattern is also reminiscent
of aging women. Although every woman will undergo meno-
pause and experience high circulating FSH and LH levels
along with some form of hormonal imbalance, not all will de-
velop ovarian tumors and not all will acquire the OSE type
on aging. This has been rationalized as being due to the
contribution of genetic factors or other epigenetic influences
that have not been clearly sorted out. We should also note
that in other mouse models of ovarian tumors, including
those derived from different transgenic approaches, only
up to 50% of the animals developed tumors (30). How-
ever, it is not known if hormonal imbalances occur in such
mutants. How and in what manner regulatory factors could
influence the strain of mutant mice that we and others have
studied to induce tumors in select mice remains an enigma
at this time. Thus, to fully understand the origin of disease
process, it will be highly relevant to establish early patterns
of change in the group of select cells that emerge to pro-
duce late tumors. Such maneuvers are feasible only in ex-
perimental mutant models.
Based on our previous [17] and current studies, we can
infer that aging FORKO mutants develop a mixture of
ovarian tumor types that also include epithelial ovarian
tumors (Figures 2 and 3). Our findings of two kinds of tumors
within the same ovary (Figure 3) suggest a complex mode of
cellular interactions. In our aged FORKO female mouse,
there are at least three distinct characteristics that are similar
to those of perimenopausal and postmenopausal women: 1)
a significant increase in the production of FSH and LH
(although circulating FSH remains high at all times, this
hormone could not function in FORKO mice, as all receptors
have been ablated); and 2) estrogen is virtually absent and
progesterone is reduced, but androgen level is higher
throughout life, and, finally, ovaries are depleted of oocytes.
The surface epithelium is involved in follicular rupture and
subsequent repair of the follicle wall in reproductive periods.
Although controversy remains regarding the cellular origin of
ovarian cancers [8,37], most investigators believe that ovarian
cancers develop from epithelial cells that cover the ovarian
surface or those that line inclusion cysts within the cortical
stroma. Although a significant increase in gonadotropic hor-
mones and other hormonal aberrations occurred as early
as 24 days, signs of ovarian tumors were not apparent until
8 months or much later in FORKO females. Although we have
no precise explanation at the present time for this observation,
Figure 4. (continued).
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the long latency is reminiscent of ovarian cancer in women
that occurs in later decades of life. Perhaps in addition to hor-
monal imbalances that occur in our mice, the loss of nega-
tively regulating factors accompanying oocyte disappearance
that only occurs later in life could be an additional contributor.
Oocyte loss/destruction, in combination with overproduction
of pituitary gonadotropins (particularly LH), leads to follicular
atresia, stromal hypertrophy, and ovarian epithelial adenomas
[38]. In addition, androgen contribution in generating tumors
in FORKO mutants assumes significance because of its sus-
tained high level. Thus, AR expression in > 80% of ovarian
tumors [39] and an increased risk of ovarian cancer in women
with elevated circulating levels of androgens [40] support
androgen involvement. Androgen stimulates the growth of
the OSE in guinea pigs, inducing the formation of benign
cysts, small adenomas in the ovarian parenchyma, and papil-
lomas on the ovarian surface [41].
Our PCNA data showing increased cell proliferation of
epithelial cells in tumor sections, but not in the OSE (in both
WT and atretic unaffected FORKO ovaries), are interesting.
Very little proliferation of the OSE is detectable in adult mice
[10]. In adult tissues, GATA transcription factors likely func-
tion to maintain cells in a differentiated state [42]. Loss of
GATA factors or their cognate regulatory pathways could
lead to dedifferentiation of epithelial cells, contributing to
tumorigenicity. GATA-4 is expressed in sex cord–derived
ovarian and gonad tumors [43], but is lost in some ovarian
epithelial cancers [44]. Selective loss of GATA-4 in FORKO
Figure 4. (continued).
Table 2. Expression of PCNA, GATA-4, COX-1, COX-2, PDGFR-a, and
PDGFR-b in Epithelial Cells of 12 (Plus)-Month-Old WT, FORKO, and FORKO
Tumor Ovaries.
WT FORKO FORKO Tumor
PCNA +/ +/ ++
GATA-4 ++ + +/
COX-1 +/ +/ ++
COX-2 +/ + ++
PDGFR-a + +/ ++
PDGFR-b + +/ ++
Microscopic evaluation by two independent observers not connected to
the study.
(+/) Weak signal; (+) strong signal; (++) very strong signal.
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ovarian epithelial tumor, but not in normal OSE, suggests
that affected cells undergo dedifferentiation. A higher ex-
pression of COX-1 and COX-2 in FORKO ovarian epithelial
tumors is also consistent with recent findings. It has been
shown that COX-2 is expressed in a wide variety of epithelial
cancers and that COX-1 overexpression is common to EOC,
rendering them as the primary target for various chemo-
prevention studies employing specific COX-2 inhibitors or
nonsteroidal anti-inflammatory drugs that inhibit both COX-1
and COX-2 [45]. COX-1 serves as a potential marker of EOC
[27], and COX-2 has been implicated as a tumor promoter
because it stimulates angiogenesis [46] and promotes me-
tastasis [47], suggesting that overexpression of both COX-1
and COX-2 may have contributed to tumorigenic potential.
As both PDGFR-a and PDGFR-b are expressed strongly
in ovarian serous tumors, our work implicates the PDGF
family in this process, and their inhibitors could be potential
candidates for reducing tumor burden. We propose that fur-
ther mechanistic studies in this direction be accelerated
by securing OSE-type cells from different stages in affected
FORKO mutant mice either by culturing them or by selective
capture for gene expressions.
In conclusion, we have observed that the loss of FSH-R
signaling results in alteration of the OSE in early life and that
ovarian epithelial tumor development occurs only on aging
in mutant mice. Our results provide the first in vivo evidence
that the complete elimination of FSH-R also contributes to
the initiation of OSE changes and the induction of gonadal
epithelial tumorigenesis.
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